TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16614408
Drug: (n‐3) fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (n‐3) fatty acids supplementation (3.6 g (n‐3) fatty acids/d)
Study: 12574881
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g ceftriaxone i.v. 30 min preoperatively
Study: 10566718
Drug: No study
Approvals — FDA: no, EMA: no, PMDA: no
Description: No study medication (control)
Study: 24621069
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g of a proprietary mixture of non-starch polysaccharides (NSPs) (Ambrotose® complex)
Study: 12050835
Drug: Ice therapy
Normalized name: Ice Therapy
DrugBank: Levomenthol (DB00825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ice therapy before chest tube removal
Study: 7575134
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) inhalation, 800 micrograms/day, twice daily (group A)
Study: 7575134
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) inhalation, 800 micrograms/day, four times daily (group B)
Study: 1720012
Drug: Clodronate (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (600 mg iv as a single dose infused over several hours)
Study: 1720012
Drug: Clodronate (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (oral administration, longer-term effects)
Study: 7020779
Drug: No-treatment Control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment Control (C)
Study: 25106731
Drug: FOLFIRI (5-fluorouracil/leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI (5-fluorouracil/leucovorin with irinotecan) in patients who received prior chemotherapy containing oxaliplatin
Study: 25106731
Drug: IRIS (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRIS (irinotecan plus S-1) in patients who received prior chemotherapy containing oxaliplatin
Study: 12646120
Drug: Modified extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified extract of Parietaria judaica pollen (depigmented and glutaraldehyde‐polymerized), treatment schedule: incremental phase of 5 injections and maintenance dosage of 0.5 ml per month, total of 14 injections over 12 months
Study: 12646120
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no specific immunotherapy)
Study: 10771448
Drug: Ziprasidone 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 10 mg day(-1)
Study: 10771448
Drug: Ziprasidone 40
Normalized name: ziprasidone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 40 mg day(-1)
Study: 10771448
Drug: Ziprasidone 40-80
Normalized name: ziprasidone 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 40-80 mg day(-1)
Study: 10771448
Drug: Ziprasidone 40-120
Normalized name: ziprasidone 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 40-120 mg day(-1)
Study: 10771448
Drug: Ziprasidone (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (various doses)
Study: 8834415
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg haloperidol with nefazodone
Study: 1731545
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of 0.9% saline
Study: 1731545
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of 0.5% (5 mg) lidocaine
Study: 1731545
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of 1% (10 mg) lidocaine
Study: 1731545
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of 2% (20 mg) lidocaine
Study: 6439286
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg twice daily for four weeks
Study: 6439286
Drug: Naproxen 250
Normalized name: naproxen 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 250 mg twice daily for four weeks
Study: 6439286
Drug: Sulindac 200
Normalized name: sulindac 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac 200 mg twice daily for four weeks
Study: 6439286
Drug: Hydrochlorothiazide 50
Normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 50 mg a day (diuretic treatment)
Study: 30625023
Drug: Financial Counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Financial Counseling (FC) intervention including education, financial assistance screening, and an estimation tool for out-of-pocket costs of chemotherapy.
Study: 23017609
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care with music therapy
Study: 8995042
Drug: Spouse-aided treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spouse-aided treatment
Study: 8995042
Drug: Individual behavioral-cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual behavioral-cognitive therapy
Study: 31005945
Drug: Workshop and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Workshop and weekly reminders (WR)
Study: 29239682
Drug: Trivalent seasonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent seasonal influenza vaccine (15 μg of hemagglutinin per strain)
Study: 25197826
Drug: Brief alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief alcohol intervention (6 counseling sessions approximately monthly)
Study: 22793966
Drug: Midazolam (0.5mg.kg(‐1))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.5mg.kg(‐1)) in 5 mL fruit juice
Study: 20460227
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (Low dose: 85 mg/d)
Study: 20460227
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (Medium dose: 230 mg/d)
Study: 20460227
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (High dose: 500 mg/d)
Study: 15893155
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg HYD/500 mg ACET
Study: 15893155
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg HYD/500 mg ACET
Study: 15893155
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg HYD/1000 mg ACET
Study: 15893155
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg morphine sulfate (MOR)
Study: 15893155
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg ACET
Study: 12739903
Drug: Cognitive rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive rehabilitation treatment
Study: 2563735
Drug: Euglycemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycemic clamp protocol (plasma glucose approximately 5.6 mmol/L) for 4 h
Study: 2563735
Drug: Hyperglycemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemic clamp protocol (plasma glucose about 11 mmol/L) for 4 h
Study: 25300574
Drug: Oral ginger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ginger
Study: 19349870
Drug: Lopinavir-ritonavir monotherapy
Normalized name: lopinavir / ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir-ritonavir monotherapy
Study: 18097218
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (lopinavir-ritonavir and two nucleosides)
Study: 9368551
Drug: Intravenous tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue plasminogen activator (t-PA)
Study: 15619390
Drug: Chlorthalidone (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (12.5 to 25.0 mg/day)
Study: 15619390
Drug: Diuretic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic therapy (subjects who developed diabetes during treatment)
Study: 7749698
Drug: Local injection
Normalized name: Sclerosing agents for local injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injection of adrenaline (1:10,000) followed by heater probe thermocoagulation
Study: 7749698
Drug: No endoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No endoscopic treatment
Study: 1921531
Drug: Protocol for
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol for characterizing drug-related problems
Study: 30003839
Drug: Brief guided
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief guided cognitive behavioral treatment (CBT) for perfectionism delivered via a self-help booklet
Study: 27477473
Drug: Cervicothoracic manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervicothoracic manual therapy plus exercise therapy
Study: 22340428
Drug: JNJ-38431055 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-38431055 (100 mg single-dose)
Study: 22340428
Drug: JNJ-38431055 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-38431055 (500 mg single-dose)
Study: 22340428
Drug: JNJ-38431055 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-38431055 (500 mg once daily for 14 days)
Study: 22340428
Drug: Sitagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (100 mg single-dose)
Study: 20090397
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (CBT) consisting of ten consecutive weekly sessions
Study: 17678902
Drug: Oral desogestrel
Normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral desogestrel (n = 30) for 10 days combined with a tablet of raloxifene (60 mg) per vaginam (group A)
Study: 17678902
Drug: Oral desogestrel
Normalized name: Desogestrel
DrugBank: Desogestrel (DB00304)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral desogestrel at 60 mg/day (n = 30; group B)
Study: 17678902
Drug: Oral danazol
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral danazol at 200 mg, three times a day (n = 30; group C)
Study: 16236844
Drug: Inhaled nebulized
Normalized name: Hydra-Neb Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nebulized racemic glycopyrrolate (0.5, 1.0, and 2.0 mg)
Study: 10543650
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of nonionic contrast material (300 mg I/mL) at 2 mL/s
Study: 10543650
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of nonionic contrast material (300 mg I/mL) at 1.5 mL/s
Study: 10543650
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of nonionic contrast material (300 mg I/mL) at 3 mL/s
Study: 10543650
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of nonionic contrast material (300 mg I/mL) at 4 mL/s
Study: 7762723
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccination (first dose)
Study: 7762723
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccination (two doses)
Study: 1702885
Drug: Gordox therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gordox therapy (2 M IU within 20 min after induction, followed by 0.5 M IU/hour infusion until end of operation)
Study: 1702885
Drug: Gordox therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gordox therapy
Study: 206826
Drug: Clofibate and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofibate and beta-pyridylcarbinol (1.000 mg clofibrate and 50 mg beta-pyridylcarbinol per day)
Study: 206826
Drug: Clofibate (1.500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofibate (1.500 mg per day)
Study: 9568752
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg daily plus cholestyramine 4 g daily
Study: 7887103
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% wound infiltration (10 ml)
Study: 10600086
Drug: Amprenavir 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amprenavir 1200 mg
Study: 10600086
Drug: Amprenavir 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amprenavir 1200 mg plus Ketoconazole 400 mg
Study: 8743497
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein diet (0.58 g/kg body wt/day)
Study: 8743497
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low protein diet (0.28 g/kg body wt/day supplemented with keto acids and amino acids)
Study: 8743497
Drug: Usual protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual protein diet (1.3 g/kg body wt/day)
Study: 28835586
Drug: ≤15 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: ≤15 mg/day additive tolvaptan (TLV)
Study: 28835586
Drug: ≤40 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: ≤40 mg/day increased furosemide (FUR)
Study: 26911639
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 1,600 mg once daily
Study: 26911639
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 1,200 mg once daily
Study: 24362944
Drug: Telaprevir (TVR)
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir (TVR) plus PEG‐IFN and ribavirin therapy
Study: 24362944
Drug: Telaprevir (TVR)
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir (TVR) plus PEG‐IFN and ribavirin therapy with IFNL4 TT/TT genotype
Study: 24362944
Drug: Telaprevir (TVR)
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir (TVR) plus PEG‐IFN and ribavirin therapy with IFNL4 TT/ΔG or ΔG/ΔG genotypes
Study: 24362944
Drug: Telaprevir (TVR)
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir (TVR) at a reduced dose of 1,500 mg per day
Study: 24362944
Drug: Younger patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Younger patients (≤65 years) receiving the same therapy
Study: 17570908
Drug: Medication-free control
Normalized name: zinc pyrithione Medicated Shampoo [Dial Dandruff Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-free control group
Study: 15468027
Drug: Multiwavelength light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiwavelength light therapy (14 sessions, 3 times a week, energy used was 4.5 J/cm(2))
Study: 15468027
Drug: Multiwavelength light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiwavelength light therapy (for stage 3 and 4 ulcers)
Study: 15468027
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (control group for stage 3 and 4 ulcers)
Study: 11696741
Drug: 5 mg.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg. oxybutynin orally
Study: 11696741
Drug: Passive diffusion
Normalized name: LUNG DIFFUSION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive diffusion of 5 mg. oxybutynin intravesically
Study: 11696741
Drug: Electromotive administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electromotive administration of 15 mg. oxybutynin
Study: 8027416
Drug: Levodopa (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (up to 7 mg/kg per day) and Carbidopa (100 mg/day)
Study: 8027416
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (four times a day)
Study: 4348345
Drug: p-hydroxynorephedrine (PHN)
Normalized name: Hydroxynorephedrine
DrugBank: Metaraminol (DB00610)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: p-hydroxynorephedrine (PHN) 600 mg daily
Study: 27633880
Drug: CRS +
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CRS + HIPEC with lobaplatin 50 mg/m² and docetaxel 60 mg/m² in 6000 mL of normal saline at 43 ± 0.5 °C for 60 min
Study: 18209013
Drug: FLIRI (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLIRI (irinotecan 180 mg/m(2) on day 1, 5‐FU 500 mg/m(2) and FA 60 mg/m(2) on day 1 and 2)
Study: 18209013
Drug: Lv5FU2-IRI (irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lv5FU2-IRI (irinotecan 180 mg/m(2) on day 1, FA 200 mg/m(2), 5‐FU bolus 400 mg/m(2) and infused 5‐FU 600 mg/m(2) on day 1 and 2)
Study: 15180233
Drug: Early individualized
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early individualized postoperative occupational therapy (OT) program
Study: 11281614
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (2 x 500 mg tablets daily)
Study: 9885441
Drug: Response-oriented induction
Normalized name: Besponsa Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Response-oriented induction therapy consisting of doxorubicin, vincristine, cyclophosphamide, L-asparaginase, and prednisolone.
Study: 9885441
Drug: Response-oriented induction
Normalized name: Besponsa Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Response-oriented induction therapy with intrathecal chemotherapy on day 8.
Study: 9885441
Drug: Response-oriented induction
Normalized name: Besponsa Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Response-oriented induction therapy without intrathecal chemotherapy on day 8.
Study: 7994784
Drug: TUR +
Normalized name: Trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TUR + intravesical epirubicin (20 mg/40 ml, 30 times/2 years)
Study: 23867958
Drug: Early inhaled
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early inhaled nitric oxide (iNO)
Study: 21224020
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine 10mg
Study: 16373993
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g of alpha-cyclodextrin (control)
Study: 16373993
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of alpha-cyclodextrin
Study: 16373993
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of alpha-cyclodextrin
Study: 16373993
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of alpha-cyclodextrin
Study: 16373993
Drug: alpha-cyclodextrin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-cyclodextrin (all doses)
Study: 16373993
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of alpha-cyclodextrin
Study: 15037882
Drug: Standard behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard behavioral treatment with exercise level of 4186 kJ/week (1000 kcal/week)
Study: 15037882
Drug: Standard behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard behavioral treatment with exercise level of 10465 kJ/week (2500 kcal/week)
Study: 10910003
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) treatment (0.04 IU/kg) for 4 weeks
Study: 9533345
Drug: 5% Amlexanox
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% Amlexanox oral paste (Aphthasol)
Study: 8276984
Drug: Flurbiprofen, 50
Normalized name: Flurbiprofen, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen, 50 mg b.d. for 21 days
Study: 8276984
Drug: Flurbiprofen, 50
Normalized name: Flurbiprofen, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen, 50 mg b.d. for 7 days (post-treatment)
Study: 2882767
Drug: elixir preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: elixir preparation of temazepam
Study: 2882767
Drug: capsule preparation
Normalized name: bovine joint capsule preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule preparation of temazepam
Study: 23929260
Drug: L-AGE meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-AGE meal (steamed)
Study: 18334867
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (CBT) in addition to mebeverine
Study: 15616772
Drug: FAM (chemotherapy)
Normalized name: fam-trastuzumab deruxtecan-nxki Injection [Enhertu]
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAM (chemotherapy)
Study: 11335732
Drug: Reduced osmolarity
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced osmolarity ORS solution
Study: 9267272
Drug: Preemptive analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive analgesia with a combination of lidocaine hydrochloride and bupivacaine hydrochloride
Study: 9267272
Drug: Preemptive analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive analgesia with saline solution
Study: 3554125
Drug: Amoxicillin-clavulanate potassium
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanate potassium
Study: 30446405
Drug: One G
Normalized name: Arlatone G
Approvals — FDA: no, EMA: no, PMDA: no
Description: One G (OG) files (Micro‐Mega, Besançon, France)
Study: 29678195
Drug: Attention‐matched motor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attention‐matched motor therapy
Study: 22237688
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (G+MET)
Study: 22237688
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin (NPH+MET)